Neurogene Inc. (NGNE) Stock Price & Analysis

Neurogene Inc. (NGNE) rose 0.73% to USD 28.81 as of June 10, 2026 at 02:29 UTC, according to Nexqual real-time market data.

NGNE last closed at USD 28.6; the session ranged USD 24.91–29.88 on volume of 548,747 shares. Market capitalization is $455.25M, with a 52-week range of USD 14.65–37.27 (NGM). Source: Nexqual, June 10, 2026 at 02:29 UTC.

Key Statistics (as of June 10, 2026 at 02:29 UTC)

Technical Analysis (NGNE)

Nexqual's technical model rates NGNE "STRONG BUY" based on 5 bullish and 0 bearish signals across 124 daily candles, as of June 10, 2026 at 02:29 UTC.

Analyst Ratings (NGNE)

Wall Street analysts rate NGNE "Strong Buy" based on 7 analysts, with a mean price target of USD 80 (range USD 46–180), per Nexqual as of June 10, 2026 at 02:29 UTC.

Earnings (NGNE)

Recent Earnings History

Source: Nexqual, June 10, 2026 at 02:29 UTC.

Financials & Fundamentals (NGNE)

Source: Nexqual, June 10, 2026 at 02:29 UTC.

Financial Health Score (NGNE)

Nexqual rates Neurogene Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 02:29 UTC.

Ownership (NGNE)

Source: Nexqual, June 10, 2026 at 02:29 UTC.

Leadership (NGNE)

Neurogene Inc. is led by Rachel L. McMinn (age 52), Founder, Executive Chair & CEO, per Nexqual as of June 10, 2026 at 02:29 UTC.

Major Backers & Investors (NGNE)

Notable institutional backers of Neurogene Inc. include Samsara BioCapital, LLC, Redmile Group, LLC, Casdin Capital, LLC, according to Nexqual as of June 10, 2026 at 02:29 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, June 10, 2026 at 02:29 UTC.

From Neurogene Inc.'s Latest SEC 10-K Filing (filed 2026-03-24)

Key Strengths & Strategy (as disclosed to the SEC)

• The benefits of Breakthrough Therapy designation include eligibility for Priority Review, rolling submission of sections of the Biologics License Application and the FDA's organizational commitment to help determine an efficient route to approval.
• Intellectual Property We actively seek to protect our proprietary technology, inventions, and other intellectual property that is commercially important to the development of our business by a variety of means, including seeking, maintaining, and defending patent rights, whether developed internally or licensed from third parties.
• We also may rely on trade secrets and know-how relating to our proprietary technology platform, including our EXACT platform technology, on continuing technological innovation and on in-licensing opportunities that may be important for the development of our business to develop, strengthen and maintain the strength of our position in the field of gene therapy.
• One approach we are taking harnesses our proprietary transgene regulation technology, EXACT TM (Expression Attenuation via Construct Tuning), that utilizes microRNA-based genetic circuits designed to deliver therapeutic levels of transgene to key areas of the brain that underlie neurological disease pathology.

Partnerships

• License Agreement with Virovek In September 2020, we entered into a Non-Exclusive License Agreement with Virovek, Inc., pursuant to which we have a license to use certain patents and know-how on a non-exclusive basis related to our baculovirus process in exchange for low single-digit percentage royalties on future commercial net sales of each product using the baculovirus process, development milestone payments of up to $0.2 million in the aggregate, and a nonrefundable annual license fee.
• License Agreement with Sigma-Aldrich Co In January 2023, we entered into a Non-Exclusive License Agreement with Sigma-Aldrich Co.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:29 UTC. This page is informational and not investment advice.